Evidence map›Paper›PMID 33057430›Full record

ArticlePloS one2020

SR-BI mediates neutral lipid sorting from LDL to lipid droplets and facilitates their formation.

Tatyana G Vishnyakova, Alexander V Bocharov, Irina N Baranova, Roger Kurlander, Steven K Drake, Zhigang Chen, Marcelo Amar, Denis Sviridov, Boris Vaisman, Eugenia Poliakov and 3 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Tatyana G VishnyakovaClinical Center, The National Institutes of Health, Bethesda, Maryland, United States of America.ORCID 0000-0002-5189-672X
Alexander V BocharovClinical Center, The National Institutes of Health, Bethesda, Maryland, United States of America.
Irina N BaranovaClinical Center, The National Institutes of Health, Bethesda, Maryland, United States of America.ORCID 0000-0003-4250-1340
Roger KurlanderClinical Center, The National Institutes of Health, Bethesda, Maryland, United States of America.
Steven K DrakeClinical Center, The National Institutes of Health, Bethesda, Maryland, United States of America.
Zhigang ChenClinical Center, The National Institutes of Health, Bethesda, Maryland, United States of America.
Marcelo AmarNational Heart, Lung and Blood Institute, Bethesda, Maryland, United States of America.
Denis SviridovNational Heart, Lung and Blood Institute, Bethesda, Maryland, United States of America.
Boris VaismanNational Heart, Lung and Blood Institute, Bethesda, Maryland, United States of America.
Eugenia PoliakovNational Eye Institute, Bethesda, Maryland, United States of America.
Alan T RemaleyNational Heart, Lung and Blood Institute, Bethesda, Maryland, United States of America.
Thomas L EggermanClinical Center, The National Institutes of Health, Bethesda, Maryland, United States of America.
Amy P PattersonClinical Center, The National Institutes of Health, Bethesda, Maryland, United States of America.
National Institutes of Health Clinical Center · USNational Heart Lung and Blood Institute · USNational Eye Institute · USNational Institute of Diabetes and Digestive and Kidney Diseases · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

SR-BI binds various lipoproteins, including HDL, LDL as well as VLDL, and mediates selective cholesteryl ester (CE) uptake. HDL derived CE accumulates in cellular lipid droplets (LDs), which also store triacylglycerol (TAG). We hypothesized that SR-BI could significantly facilitate LD formation, in part, by directly transporting LDL derived neutral lipids (NL) such as CE and TAG into LDs without lipolysis and de novo lipid synthesis. SR-BI overexpression greatly increased LDL uptake and LD formation in stably transfected HeLa cells (SR-BI-HeLa). LDs isolated from SR-BI-HeLa contained 4- and 7-times more CE and TAG, respectively, than mock-transfected HeLa (Mock-HeLa). In contrast, LDL receptor overexpression in HeLa (LDLr-HeLa) greatly increased LDL uptake, degradation with moderate 1.5- and 2-fold increases of CE and TAG, respectively. Utilizing CE and TAG analogs, BODIPY-TAG (BP-TAG) and BODIPY-CE (BP-CE), for tracking LDL NL, we found that after initial binding of LDL to SR-BI-HeLa, apoB remained at the cell surface, while BP-CE and BP-TAG were sorted and simultaneously transported together to LDs. Both lipids demonstrated limited internalization to lysosomes or endoplasmic reticulum in SR-BI-HeLa. In LDLr-HeLa, NLs demonstrated clear lysosomal sequestration without their sorting to LDs. An inhibition of TAG and CE de novo synthesis by 90-95% only reduced TAG and CE LD content by 45-50%, and had little effect on BP-CE and BP-TAG transport to LDs in SR-BI HeLa. Furthermore, intravenous infusion of 1-2 mg of LDL increased liver LDs in normal (WT) but not in SR-BI KO mice. Mice transgenic for human SR-BI demonstrated higher liver LD accumulation than WT mice. Finally, Electro Spray Infusion Mass Spectrometry (ESI-MS) using deuterated d-CE found that LDs accumulated up to 40% of unmodified d-CE LDL. We conclude that SR-BI mediates LDL-induced LD formation in vitro and in vivo. In addition to cytosolic NL hydrolysis and de novo lipid synthesis, this process includes selective sorting and transport of LDL NL to LDs with limited lysosomal NL sequestration and the transport of LDL CE, and TAG directly to LDs independently of de novo synthesis.

Indexed as

AnimalsBiological TransportBoron CompoundsCholesterol EstersCoenzyme A LigasesEnzyme InhibitorsHeLa CellsHumansLipid DropletsLipidsLipoproteins, LDLLiverLysosomesMice, Inbred C57BLMice, KnockoutReceptors, LDL4,4-difluoro-4-bora-3a,4a-diaza-s-indaceneBoron CompoundsCholesterol EstersCoenzyme A LigasesEnzyme InhibitorsLipidsLipoproteins, LDLReceptors, LDLScavenger Receptors, Class Btriacsin CTriazenesTriglycerides

Identifiers

PMID33057430
PMCPMC7561250
OpenAlexW3093118962

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.